Literature DB >> 18190619

Comparing treatments in the presence of crossing survival curves: an application to bone marrow transplantation.

Brent R Logan1, John P Klein1, Mei-Jie Zhang1.   

Abstract

In some clinical studies comparing treatments in terms of their survival curves, researchers may anticipate that the survival curves will cross at some point, leading to interest in a long-term survival comparison. However, simple comparison of the survival curves at a fixed point may be inefficient, and use of a weighted log-rank test may be overly sensitive to early differences in survival. We formulate the problem as one of testing for differences in survival curves after a prespecified time point, and propose a variety of techniques for testing this hypothesis. We study these methods using simulation and illustrate them on a study comparing survival for autologous and allogeneic bone marrow transplants.

Entities:  

Mesh:

Year:  2008        PMID: 18190619      PMCID: PMC2754119          DOI: 10.1111/j.1541-0420.2007.00975.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   1.701


  7 in total

1.  Confidence bands for the difference of two survival curves under proportional hazards model.

Authors:  M J Zhang; J P Klein
Journal:  Lifetime Data Anal       Date:  2001-09       Impact factor: 1.588

2.  Regression modeling of competing risks data based on pseudovalues of the cumulative incidence function.

Authors:  John P Klein; Per Kragh Andersen
Journal:  Biometrics       Date:  2005-03       Impact factor: 2.571

3.  Analyzing survival curves at a fixed point in time.

Authors:  John P Klein; Brent Logan; Mette Harhoff; Per Kragh Andersen
Journal:  Stat Med       Date:  2007-10-30       Impact factor: 2.373

4.  A partially grouped logrank test.

Authors:  R Sposto; D Stablein; S Carter-Campbell
Journal:  Stat Med       Date:  1997-03-30       Impact factor: 2.373

5.  Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data.

Authors:  M S Pepe; T R Fleming
Journal:  Biometrics       Date:  1989-06       Impact factor: 2.571

6.  Procedures for comparing samples with multiple endpoints.

Authors:  P C O'Brien
Journal:  Biometrics       Date:  1984-12       Impact factor: 2.571

7.  Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

Authors:  Koen van Besien; Fausto R Loberiza; Ruta Bajorunaite; James O Armitage; Asad Bashey; Linda J Burns; Cesar O Freytes; John Gibson; Mary M Horowitz; David J Inwards; David I Marks; Rodrigo Martino; Richard T Maziarz; Arturo Molina; Santiago Pavlovsky; Andrew L Pecora; Harry C Schouten; Thomas C Shea; Hillard M Lazarus; J Douglas Rizzo; Julie M Vose
Journal:  Blood       Date:  2003-07-31       Impact factor: 22.113

  7 in total
  18 in total

1.  Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival.

Authors:  Henk M Lokhorst; Bronno van der Holt; Jan J Cornelissen; Marie José Kersten; Marinus van Oers; Reinier Raymakers; Monique C Minnema; Sonja Zweegman; Gerard Bos; Nicolaas Schaap; Shulamiet Wittebol; Okke de Weerdt; Rianne Ammerlaan; Pieter Sonneveld
Journal:  Haematologica       Date:  2015-09-04       Impact factor: 9.941

2.  Cutpoint selection for discretizing a continuous covariate for generalized estimating equations.

Authors:  Gisela Tunes-da-Silva; John P Klein
Journal:  Comput Stat Data Anal       Date:  2011-01-01       Impact factor: 1.681

3.  Comments on the utilization of Mann-Whitney U test and Kaplan-Meier method.

Authors:  Jian Xie; Lang Li
Journal:  J Gynecol Oncol       Date:  2021-05       Impact factor: 4.401

4.  Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation.

Authors:  Frank Peinemann; Elvira C van Dalen; Heike Enk; Godelieve Am Tytgat
Journal:  Cochrane Database Syst Rev       Date:  2019-04-24

5.  Treatment with GM-CSF secreting myeloid leukemia cell vaccine prior to autologous-BMT improves the survival of leukemia-challenged mice.

Authors:  Jenny Zilberberg; Thea M Friedman; Glenn Dranoff; Robert Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-12       Impact factor: 5.742

6.  Generalized accelerated failure time spatial frailty model for arbitrarily censored data.

Authors:  Haiming Zhou; Timothy Hanson; Jiajia Zhang
Journal:  Lifetime Data Anal       Date:  2016-03-18       Impact factor: 1.588

Review 7.  Group sequential tests for long-term survival comparisons.

Authors:  Brent R Logan; Shuyuan Mo
Journal:  Lifetime Data Anal       Date:  2014-07-23       Impact factor: 1.588

8.  Analyzing survival curves at a fixed point in time for paired and clustered right-censored data.

Authors:  Pei-Fang Su; Yunchan Chi; Chun-Yi Lee; Yu Shyr; Yi-De Liao
Journal:  Comput Stat Data Anal       Date:  2010-10-21       Impact factor: 1.681

9.  Multivariate permutation test to compare survival curves for matched data.

Authors:  Stefania Galimberti; Maria Grazia Valsecchi
Journal:  BMC Med Res Methodol       Date:  2013-02-11       Impact factor: 4.615

10.  Intensive care outcomes in bone marrow transplant recipients: a population-based cohort analysis.

Authors:  Damon C Scales; Deva Thiruchelvam; Alexander Kiss; William J Sibbald; Donald A Redelmeier
Journal:  Crit Care       Date:  2008-06-11       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.